Navigating Sertraline During Pregnancy: Weighing Maternal Mental Health Against Fetal Risk

For many women, a positive pregnancy test arrives alongside an already-complicated relationship with their mental health. If you are currently taking sertraline — or have been considering it — a pregnancy diagnosis does not automatically mean you must stop. It does, however, mean that the conversation with your prescribing clinician becomes significantly more layered.

This article does not offer medical advice or a universal recommendation. What it does offer is a clear-eyed look at what the research currently shows, what federal guidance says, and how to think through the decision in partnership with a qualified provider.

Why This Decision Is Rarely Black and White

Depression and anxiety during pregnancy — collectively referred to as perinatal mood and anxiety disorders — are among the most common complications of pregnancy in the United States, affecting an estimated 10 to 20 percent of pregnant women. Left untreated, these conditions carry their own documented risks: poor prenatal care adherence, inadequate nutrition, disrupted sleep, and in severe cases, self-harm or suicidal ideation.

This is the central tension that clinicians and patients must confront together. Discontinuing an antidepressant during pregnancy is not inherently the "safe" choice. Untreated maternal mental illness carries measurable consequences for both mother and developing child. The question, therefore, is never simply whether sertraline poses risks — it is whether those risks outweigh the risks of going without treatment.

What the Current Research Shows

Sertraline is one of the most studied antidepressants in the context of pregnancy, in part because it has been in widespread use since the early 1990s. Here is a summary of what the evidence currently indicates:

Fetal development and birth defects. The majority of large observational studies have not found a statistically significant association between sertraline use and major congenital malformations. Some earlier studies raised concerns about a potential link to cardiac septal defects, but more recent and methodologically rigorous research has largely not confirmed this association. The absolute risk, even in studies that did find a signal, remained very small.

Preterm birth and low birth weight. Some data suggest a modest association between SSRI use in late pregnancy and slightly increased rates of preterm delivery or reduced birth weight. However, it is difficult to isolate the medication's effect from the underlying psychiatric condition itself, which is also associated with these outcomes.

Neonatal adaptation syndrome. Infants born to mothers who took sertraline close to delivery may experience a short-term cluster of symptoms — jitteriness, feeding difficulties, mild respiratory changes, and irritability — sometimes called neonatal adaptation syndrome. This typically resolves within a few days without medical intervention and is generally considered manageable rather than dangerous.

Persistent pulmonary hypertension of the newborn (PPHN). Some studies have identified a small increased risk of PPHN associated with SSRI use in late pregnancy. The FDA issued a safety communication on this topic in 2011. The absolute risk remains low, but it is a factor that should be discussed with your obstetric and psychiatric care team.

Long-term neurodevelopmental outcomes. Research examining whether prenatal SSRI exposure affects cognitive development, behavioral outcomes, or autism spectrum disorder risk has produced mixed findings. Many of the studies that initially suggested associations have been criticized for failing to adequately control for maternal psychiatric illness as a confounding variable. Current consensus does not support a definitive causal link, but research is ongoing.

FDA Classification and What It Means in Practice

Sertraline is currently classified under the FDA's updated labeling framework, which replaced the older A/B/C/D/X letter system with more detailed narrative summaries. The prescribing information for sertraline includes data from available human studies and notes the potential for neonatal adaptation syndrome when exposure occurs near term.

Importantly, FDA labeling does not prohibit sertraline use during pregnancy. It requires that prescribers and patients make individualized decisions based on a risk-benefit analysis. The agency explicitly acknowledges that untreated psychiatric disorders themselves carry risk — language that reflects a more nuanced regulatory posture than older frameworks allowed.

Considerations for Breastfeeding

Sertraline is generally considered one of the preferred antidepressants for breastfeeding mothers, based on its pharmacological profile and available data. It transfers into breast milk at relatively low levels, and infant serum concentrations reported in studies have typically been low or undetectable. No significant adverse effects in nursing infants have been consistently documented.

Organizations including the American Academy of Pediatrics and LactMed — the National Institutes of Health's database on drugs and lactation — list sertraline as compatible with breastfeeding, though they recommend monitoring the infant for any unusual symptoms. As with all medications during this period, ongoing communication with your pediatrician and prescribing clinician is warranted.

How to Approach the Conversation With Your Provider

If you are pregnant or planning to become pregnant and currently take sertraline, the following steps can help you navigate the process more effectively:

Do not discontinue on your own. Abruptly stopping sertraline can trigger discontinuation syndrome and may cause a rapid return of depressive or anxiety symptoms at an already demanding time. Any changes to your medication regimen should be made under clinical supervision.

Request a coordinated care conversation. Ideally, your OB-GYN or midwife and your psychiatrist or prescribing clinician should be in communication with one another. If your care is fragmented, ask about a joint consultation or request that your providers share records.

Discuss your specific psychiatric history. The severity and history of your condition matters enormously. A woman with a single mild depressive episode that has been in remission for two years faces a very different calculus than a woman with recurrent severe depression or a history of hospitalization.

Ask about alternatives and adjunct therapies. In some cases — particularly for milder presentations — cognitive behavioral therapy (CBT) or other evidence-based psychotherapies may be appropriate either as a standalone approach or in combination with a lower medication dose. This is a conversation worth having explicitly.

Revisit the plan at each trimester. Pregnancy is not static, and neither are the relevant considerations. What is appropriate in the first trimester may warrant reassessment in the third, particularly around the question of dosing close to the delivery date.

The Broader Principle: Informed Decisions Over Blanket Rules

There is no universal answer to whether sertraline should be used during pregnancy. What exists is a growing body of evidence, a set of clinical guidelines, and a framework for individualized decision-making. The goal is not to eliminate all risk — that is not possible in any medical decision — but to understand the relative risks and make a choice that reflects your specific circumstances, values, and health history.

Expecting mothers deserve access to accurate, non-alarmist information so that fear alone does not drive treatment decisions in either direction. If you are struggling with this question, a consultation with a perinatal psychiatrist — a specialist in mental health care during pregnancy and the postpartum period — can provide an additional layer of expertise that general practitioners may not be positioned to offer.

Your mental health is not secondary to your pregnancy. Both matter, and both deserve careful, evidence-informed attention.